Inhibition of EGFR Signaling: All Mutations Are Not Created Equal
Open Access
- 29 November 2005
- journal article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 2 (11), e377
- https://doi.org/10.1371/journal.pmed.0020377
Abstract
Gazdar and Minna discuss the context and implications of a research article that examines the transformation potential and response to inhibitors of specific EGFR mutations found in lung cancer.Keywords
This publication has 14 references indexed in Scilit:
- Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR MutantsPLoS Medicine, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung CancersJNCI Journal of the National Cancer Institute, 2005
- Mutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers?Trends in Molecular Medicine, 2004
- Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic PathwaysScience, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinicCancer Immunology, Immunotherapy, 2003
- The protein tyrosine kinase family of the human genomeOncogene, 2000